Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Genitourinary 1

Conditions

Breast Neoplasms 4Neoplasms, Hormone-Dependent 3Carcinoma, Lobular 3Carcinoma, Ductal, Breast 3Prostatic Neoplasms 2Prostatic Intraepithelial Neoplasia 2Fractures, Bone 2Precancerous Conditions 1Osteoporosis 1Neoplasms 1Bone Diseases, Metabolic 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × Toremifene × Clear all
NCT00106691 2023-06-12

Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)

GTx

Phase 3 Completed
1,589 enrolled 16 charts
GenitourinaryOther neoplasm

Neoplasms, Precancerous Conditions, Prostatic Intraepithelial Neoplasia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡